Biomolecules-期刊论坛，投稿经验-MedSci.cn

[GetPortalCommentsPageByObjectIdResponse(id=955355, encodeId=1dba95535579, content=审稿速度:2.0 | 投稿命中率:50.0 经验分享：3.5 投稿 3.10 under review 3.24 major revised 3.29 resubmited 4.7 minor revised 4.7 resubmited 4.8 accepted 审稿很有效率，审稿人也很耐心专业，问题很尖锐，知道哪里是痛点……, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=142, replyNumber=15, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=34a12034709, createdName=1891e859aem, createdTime=Fri Apr 09 00:42:05 CST 2021, time=2021-04-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1208392, encodeId=2e5f1208392a9, content=审稿速度:2.0 | 投稿命中率:25.0 偏重的研究方向：分子相关 经验分享：投过，正文和sup的western需要原始扫描图片，投之前请准备好, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=73, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/08/29/61916d37f00260943d1aefc338a64a59.jpg, createdBy=9ee81954970, createdName=柠檬cherry, createdTime=Sun Apr 03 17:35:10 CST 2022, time=2022-04-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2111397, encodeId=c435211139ec9, content=审稿速度:3.0 | 投稿命中率:50.0 偏重的研究方向：肿瘤 经验分享：送审要多久才能有一审结果，得两周以上吗，着急毕业, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=37, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6cd78382265, createdName=ms8000000557693802, createdTime=Wed Jan 25 11:25:11 CST 2023, time=2023-01-25, status=1, ipAttribution=陕西省), GetPortalCommentsPageByObjectIdResponse(id=1227071, encodeId=488a122e0710a, content=审稿速度:2.0 偏重的研究方向：蛋白;疾病;综述 经验分享：5.10第一次提交 5.25大修 6.2修回 6.10小修 6.13修回 6.14接收, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=74, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=96625632699, createdName=ms6000001129672915, createdTime=Fri Jun 17 17:02:56 CST 2022, time=2022-06-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1239747, encodeId=5d321239e47f3, content=审稿速度:1.0 | 投稿命中率:95.0 偏重的研究方向：神经病学;表观遗传学 经验分享：Submission Received：25 July 2022 Submission Revision Date: 15 August 2022 Accepted: 18 August 2022 本人是写的综述，方向比较窄但还算新，前期被拒了很多次，就试了这个，审稿速度非常快，审稿人的意见也非常nice！虽然中间因为找不到审稿人一度觉得稿子又要被拒了，但编辑都非常的和善！就算是自己出了一点点小问题也不用那么担心，真的是非常棒的期刊！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=72, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a8078157728, createdName=ms8000000344893328, createdTime=Fri Aug 19 15:45:06 CST 2022, time=2022-08-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1249357, encodeId=8746124935ee5, content=我想请问一下哈，under review是到审稿人那边了吗，还是说可能还在编辑手里啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=39, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b9f88197404, createdName=ms5000001050298954, createdTime=Fri Sep 16 16:03:31 CST 2022, time=2022-09-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2117098, encodeId=ffee211e098fe, content=偏重的研究方向：分子机制 经验分享：2.9号投稿，一周后邮件催编辑送审或拒稿，马上让改成communication，2.22送审，目前under review中，希望快快接收, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=33, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b0258470999, createdName=ms9000000723499418, createdTime=Wed Mar 01 19:39:35 CST 2023, time=2023-03-01, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2167430, encodeId=8502216e43081, content=审稿速度:1.0 | 投稿命中率:50.0 经验分享：11月1日投，11月8号大修, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=34, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=388d9023198, createdName=ms6000000755861927, createdTime=Wed Nov 08 16:52:00 CST 2023, time=2023-11-08, status=1, ipAttribution=福建省), GetPortalCommentsPageByObjectIdResponse(id=2130024, encodeId=eda7213002442, content=生信加细胞功能验证好不好投这个刊？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=35, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7ff98516862, createdName=ms2000000795035219, createdTime=Thu May 04 11:54:01 CST 2023, time=2023-05-04, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=857532, encodeId=7b3085e532d3, content=1月3投 1月8号undereview 1月20号小修五天 1月30号大修十天 2月7号修回 2月8号接收 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=95, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5bf15414154, createdName=ms3508121495608353, createdTime=Sun Feb 16 14:11:14 CST 2020, time=2020-02-16, status=1, ipAttribution=)]

2021-04-09 1891e859aem

审稿速度:2.0 | 投稿命中率:50.0
经验分享：3.5 投稿 3.10 under review 3.24 major revised 3.29 resubmited 4.7 minor revised 4.7 resubmited 4.8 accepted 审稿很有效率，审稿人也很耐心专业，问题很尖锐，知道哪里是痛点……

142 15

展开15条回复

[GetPortalCommentsPageByObjectIdResponse(id=955355, encodeId=1dba95535579, content=审稿速度:2.0 | 投稿命中率:50.0 经验分享：3.5 投稿 3.10 under review 3.24 major revised 3.29 resubmited 4.7 minor revised 4.7 resubmited 4.8 accepted 审稿很有效率，审稿人也很耐心专业，问题很尖锐，知道哪里是痛点……, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=142, replyNumber=15, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=34a12034709, createdName=1891e859aem, createdTime=Fri Apr 09 00:42:05 CST 2021, time=2021-04-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1208392, encodeId=2e5f1208392a9, content=审稿速度:2.0 | 投稿命中率:25.0 偏重的研究方向：分子相关 经验分享：投过，正文和sup的western需要原始扫描图片，投之前请准备好, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=73, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/08/29/61916d37f00260943d1aefc338a64a59.jpg, createdBy=9ee81954970, createdName=柠檬cherry, createdTime=Sun Apr 03 17:35:10 CST 2022, time=2022-04-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2111397, encodeId=c435211139ec9, content=审稿速度:3.0 | 投稿命中率:50.0 偏重的研究方向：肿瘤 经验分享：送审要多久才能有一审结果，得两周以上吗，着急毕业, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=37, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6cd78382265, createdName=ms8000000557693802, createdTime=Wed Jan 25 11:25:11 CST 2023, time=2023-01-25, status=1, ipAttribution=陕西省), GetPortalCommentsPageByObjectIdResponse(id=1227071, encodeId=488a122e0710a, content=审稿速度:2.0 偏重的研究方向：蛋白;疾病;综述 经验分享：5.10第一次提交 5.25大修 6.2修回 6.10小修 6.13修回 6.14接收, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=74, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=96625632699, createdName=ms6000001129672915, createdTime=Fri Jun 17 17:02:56 CST 2022, time=2022-06-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1239747, encodeId=5d321239e47f3, content=审稿速度:1.0 | 投稿命中率:95.0 偏重的研究方向：神经病学;表观遗传学 经验分享：Submission Received：25 July 2022 Submission Revision Date: 15 August 2022 Accepted: 18 August 2022 本人是写的综述，方向比较窄但还算新，前期被拒了很多次，就试了这个，审稿速度非常快，审稿人的意见也非常nice！虽然中间因为找不到审稿人一度觉得稿子又要被拒了，但编辑都非常的和善！就算是自己出了一点点小问题也不用那么担心，真的是非常棒的期刊！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=72, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a8078157728, createdName=ms8000000344893328, createdTime=Fri Aug 19 15:45:06 CST 2022, time=2022-08-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1249357, encodeId=8746124935ee5, content=我想请问一下哈，under review是到审稿人那边了吗，还是说可能还在编辑手里啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=39, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b9f88197404, createdName=ms5000001050298954, createdTime=Fri Sep 16 16:03:31 CST 2022, time=2022-09-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2117098, encodeId=ffee211e098fe, content=偏重的研究方向：分子机制 经验分享：2.9号投稿，一周后邮件催编辑送审或拒稿，马上让改成communication，2.22送审，目前under review中，希望快快接收, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=33, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b0258470999, createdName=ms9000000723499418, createdTime=Wed Mar 01 19:39:35 CST 2023, time=2023-03-01, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2167430, encodeId=8502216e43081, content=审稿速度:1.0 | 投稿命中率:50.0 经验分享：11月1日投，11月8号大修, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=34, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=388d9023198, createdName=ms6000000755861927, createdTime=Wed Nov 08 16:52:00 CST 2023, time=2023-11-08, status=1, ipAttribution=福建省), GetPortalCommentsPageByObjectIdResponse(id=2130024, encodeId=eda7213002442, content=生信加细胞功能验证好不好投这个刊？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=35, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7ff98516862, createdName=ms2000000795035219, createdTime=Thu May 04 11:54:01 CST 2023, time=2023-05-04, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=857532, encodeId=7b3085e532d3, content=1月3投 1月8号undereview 1月20号小修五天 1月30号大修十天 2月7号修回 2月8号接收 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=95, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5bf15414154, createdName=ms3508121495608353, createdTime=Sun Feb 16 14:11:14 CST 2020, time=2020-02-16, status=1, ipAttribution=)]

2022-04-03 柠檬cherry

审稿速度:2.0 | 投稿命中率:25.0
偏重的研究方向：分子相关
经验分享：投过，正文和sup的western需要原始扫描图片，投之前请准备好

73 8

展开8条回复

[GetPortalCommentsPageByObjectIdResponse(id=955355, encodeId=1dba95535579, content=审稿速度:2.0 | 投稿命中率:50.0 经验分享：3.5 投稿 3.10 under review 3.24 major revised 3.29 resubmited 4.7 minor revised 4.7 resubmited 4.8 accepted 审稿很有效率，审稿人也很耐心专业，问题很尖锐，知道哪里是痛点……, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=142, replyNumber=15, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=34a12034709, createdName=1891e859aem, createdTime=Fri Apr 09 00:42:05 CST 2021, time=2021-04-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1208392, encodeId=2e5f1208392a9, content=审稿速度:2.0 | 投稿命中率:25.0 偏重的研究方向：分子相关 经验分享：投过，正文和sup的western需要原始扫描图片，投之前请准备好, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=73, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/08/29/61916d37f00260943d1aefc338a64a59.jpg, createdBy=9ee81954970, createdName=柠檬cherry, createdTime=Sun Apr 03 17:35:10 CST 2022, time=2022-04-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2111397, encodeId=c435211139ec9, content=审稿速度:3.0 | 投稿命中率:50.0 偏重的研究方向：肿瘤 经验分享：送审要多久才能有一审结果，得两周以上吗，着急毕业, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=37, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6cd78382265, createdName=ms8000000557693802, createdTime=Wed Jan 25 11:25:11 CST 2023, time=2023-01-25, status=1, ipAttribution=陕西省), GetPortalCommentsPageByObjectIdResponse(id=1227071, encodeId=488a122e0710a, content=审稿速度:2.0 偏重的研究方向：蛋白;疾病;综述 经验分享：5.10第一次提交 5.25大修 6.2修回 6.10小修 6.13修回 6.14接收, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=74, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=96625632699, createdName=ms6000001129672915, createdTime=Fri Jun 17 17:02:56 CST 2022, time=2022-06-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1239747, encodeId=5d321239e47f3, content=审稿速度:1.0 | 投稿命中率:95.0 偏重的研究方向：神经病学;表观遗传学 经验分享：Submission Received：25 July 2022 Submission Revision Date: 15 August 2022 Accepted: 18 August 2022 本人是写的综述，方向比较窄但还算新，前期被拒了很多次，就试了这个，审稿速度非常快，审稿人的意见也非常nice！虽然中间因为找不到审稿人一度觉得稿子又要被拒了，但编辑都非常的和善！就算是自己出了一点点小问题也不用那么担心，真的是非常棒的期刊！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=72, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a8078157728, createdName=ms8000000344893328, createdTime=Fri Aug 19 15:45:06 CST 2022, time=2022-08-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1249357, encodeId=8746124935ee5, content=我想请问一下哈，under review是到审稿人那边了吗，还是说可能还在编辑手里啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=39, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b9f88197404, createdName=ms5000001050298954, createdTime=Fri Sep 16 16:03:31 CST 2022, time=2022-09-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2117098, encodeId=ffee211e098fe, content=偏重的研究方向：分子机制 经验分享：2.9号投稿，一周后邮件催编辑送审或拒稿，马上让改成communication，2.22送审，目前under review中，希望快快接收, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=33, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b0258470999, createdName=ms9000000723499418, createdTime=Wed Mar 01 19:39:35 CST 2023, time=2023-03-01, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2167430, encodeId=8502216e43081, content=审稿速度:1.0 | 投稿命中率:50.0 经验分享：11月1日投，11月8号大修, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=34, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=388d9023198, createdName=ms6000000755861927, createdTime=Wed Nov 08 16:52:00 CST 2023, time=2023-11-08, status=1, ipAttribution=福建省), GetPortalCommentsPageByObjectIdResponse(id=2130024, encodeId=eda7213002442, content=生信加细胞功能验证好不好投这个刊？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=35, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7ff98516862, createdName=ms2000000795035219, createdTime=Thu May 04 11:54:01 CST 2023, time=2023-05-04, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=857532, encodeId=7b3085e532d3, content=1月3投 1月8号undereview 1月20号小修五天 1月30号大修十天 2月7号修回 2月8号接收 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=95, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5bf15414154, createdName=ms3508121495608353, createdTime=Sun Feb 16 14:11:14 CST 2020, time=2020-02-16, status=1, ipAttribution=)]

2023-01-25 ms8000000557693802 来自陕西省

审稿速度:3.0 | 投稿命中率:50.0
偏重的研究方向：肿瘤
经验分享：送审要多久才能有一审结果，得两周以上吗，着急毕业

37 8

展开8条回复

[GetPortalCommentsPageByObjectIdResponse(id=955355, encodeId=1dba95535579, content=审稿速度:2.0 | 投稿命中率:50.0 经验分享：3.5 投稿 3.10 under review 3.24 major revised 3.29 resubmited 4.7 minor revised 4.7 resubmited 4.8 accepted 审稿很有效率，审稿人也很耐心专业，问题很尖锐，知道哪里是痛点……, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=142, replyNumber=15, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=34a12034709, createdName=1891e859aem, createdTime=Fri Apr 09 00:42:05 CST 2021, time=2021-04-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1208392, encodeId=2e5f1208392a9, content=审稿速度:2.0 | 投稿命中率:25.0 偏重的研究方向：分子相关 经验分享：投过，正文和sup的western需要原始扫描图片，投之前请准备好, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=73, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/08/29/61916d37f00260943d1aefc338a64a59.jpg, createdBy=9ee81954970, createdName=柠檬cherry, createdTime=Sun Apr 03 17:35:10 CST 2022, time=2022-04-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2111397, encodeId=c435211139ec9, content=审稿速度:3.0 | 投稿命中率:50.0 偏重的研究方向：肿瘤 经验分享：送审要多久才能有一审结果，得两周以上吗，着急毕业, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=37, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6cd78382265, createdName=ms8000000557693802, createdTime=Wed Jan 25 11:25:11 CST 2023, time=2023-01-25, status=1, ipAttribution=陕西省), GetPortalCommentsPageByObjectIdResponse(id=1227071, encodeId=488a122e0710a, content=审稿速度:2.0 偏重的研究方向：蛋白;疾病;综述 经验分享：5.10第一次提交 5.25大修 6.2修回 6.10小修 6.13修回 6.14接收, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=74, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=96625632699, createdName=ms6000001129672915, createdTime=Fri Jun 17 17:02:56 CST 2022, time=2022-06-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1239747, encodeId=5d321239e47f3, content=审稿速度:1.0 | 投稿命中率:95.0 偏重的研究方向：神经病学;表观遗传学 经验分享：Submission Received：25 July 2022 Submission Revision Date: 15 August 2022 Accepted: 18 August 2022 本人是写的综述，方向比较窄但还算新，前期被拒了很多次，就试了这个，审稿速度非常快，审稿人的意见也非常nice！虽然中间因为找不到审稿人一度觉得稿子又要被拒了，但编辑都非常的和善！就算是自己出了一点点小问题也不用那么担心，真的是非常棒的期刊！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=72, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a8078157728, createdName=ms8000000344893328, createdTime=Fri Aug 19 15:45:06 CST 2022, time=2022-08-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1249357, encodeId=8746124935ee5, content=我想请问一下哈，under review是到审稿人那边了吗，还是说可能还在编辑手里啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=39, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b9f88197404, createdName=ms5000001050298954, createdTime=Fri Sep 16 16:03:31 CST 2022, time=2022-09-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2117098, encodeId=ffee211e098fe, content=偏重的研究方向：分子机制 经验分享：2.9号投稿，一周后邮件催编辑送审或拒稿，马上让改成communication，2.22送审，目前under review中，希望快快接收, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=33, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b0258470999, createdName=ms9000000723499418, createdTime=Wed Mar 01 19:39:35 CST 2023, time=2023-03-01, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2167430, encodeId=8502216e43081, content=审稿速度:1.0 | 投稿命中率:50.0 经验分享：11月1日投，11月8号大修, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=34, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=388d9023198, createdName=ms6000000755861927, createdTime=Wed Nov 08 16:52:00 CST 2023, time=2023-11-08, status=1, ipAttribution=福建省), GetPortalCommentsPageByObjectIdResponse(id=2130024, encodeId=eda7213002442, content=生信加细胞功能验证好不好投这个刊？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=35, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7ff98516862, createdName=ms2000000795035219, createdTime=Thu May 04 11:54:01 CST 2023, time=2023-05-04, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=857532, encodeId=7b3085e532d3, content=1月3投 1月8号undereview 1月20号小修五天 1月30号大修十天 2月7号修回 2月8号接收 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=95, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5bf15414154, createdName=ms3508121495608353, createdTime=Sun Feb 16 14:11:14 CST 2020, time=2020-02-16, status=1, ipAttribution=)]

2022-06-17 ms6000001129672915

审稿速度:2.0
偏重的研究方向：蛋白;疾病;综述
经验分享：5.10第一次提交
5.25大修
6.2修回
6.10小修
6.13修回
6.14接收

74 6

展开6条回复

[GetPortalCommentsPageByObjectIdResponse(id=955355, encodeId=1dba95535579, content=审稿速度:2.0 | 投稿命中率:50.0 经验分享：3.5 投稿 3.10 under review 3.24 major revised 3.29 resubmited 4.7 minor revised 4.7 resubmited 4.8 accepted 审稿很有效率，审稿人也很耐心专业，问题很尖锐，知道哪里是痛点……, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=142, replyNumber=15, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=34a12034709, createdName=1891e859aem, createdTime=Fri Apr 09 00:42:05 CST 2021, time=2021-04-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1208392, encodeId=2e5f1208392a9, content=审稿速度:2.0 | 投稿命中率:25.0 偏重的研究方向：分子相关 经验分享：投过，正文和sup的western需要原始扫描图片，投之前请准备好, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=73, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/08/29/61916d37f00260943d1aefc338a64a59.jpg, createdBy=9ee81954970, createdName=柠檬cherry, createdTime=Sun Apr 03 17:35:10 CST 2022, time=2022-04-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2111397, encodeId=c435211139ec9, content=审稿速度:3.0 | 投稿命中率:50.0 偏重的研究方向：肿瘤 经验分享：送审要多久才能有一审结果，得两周以上吗，着急毕业, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=37, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6cd78382265, createdName=ms8000000557693802, createdTime=Wed Jan 25 11:25:11 CST 2023, time=2023-01-25, status=1, ipAttribution=陕西省), GetPortalCommentsPageByObjectIdResponse(id=1227071, encodeId=488a122e0710a, content=审稿速度:2.0 偏重的研究方向：蛋白;疾病;综述 经验分享：5.10第一次提交 5.25大修 6.2修回 6.10小修 6.13修回 6.14接收, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=74, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=96625632699, createdName=ms6000001129672915, createdTime=Fri Jun 17 17:02:56 CST 2022, time=2022-06-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1239747, encodeId=5d321239e47f3, content=审稿速度:1.0 | 投稿命中率:95.0 偏重的研究方向：神经病学;表观遗传学 经验分享：Submission Received：25 July 2022 Submission Revision Date: 15 August 2022 Accepted: 18 August 2022 本人是写的综述，方向比较窄但还算新，前期被拒了很多次，就试了这个，审稿速度非常快，审稿人的意见也非常nice！虽然中间因为找不到审稿人一度觉得稿子又要被拒了，但编辑都非常的和善！就算是自己出了一点点小问题也不用那么担心，真的是非常棒的期刊！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=72, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a8078157728, createdName=ms8000000344893328, createdTime=Fri Aug 19 15:45:06 CST 2022, time=2022-08-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1249357, encodeId=8746124935ee5, content=我想请问一下哈，under review是到审稿人那边了吗，还是说可能还在编辑手里啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=39, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b9f88197404, createdName=ms5000001050298954, createdTime=Fri Sep 16 16:03:31 CST 2022, time=2022-09-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2117098, encodeId=ffee211e098fe, content=偏重的研究方向：分子机制 经验分享：2.9号投稿，一周后邮件催编辑送审或拒稿，马上让改成communication，2.22送审，目前under review中，希望快快接收, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=33, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b0258470999, createdName=ms9000000723499418, createdTime=Wed Mar 01 19:39:35 CST 2023, time=2023-03-01, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2167430, encodeId=8502216e43081, content=审稿速度:1.0 | 投稿命中率:50.0 经验分享：11月1日投，11月8号大修, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=34, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=388d9023198, createdName=ms6000000755861927, createdTime=Wed Nov 08 16:52:00 CST 2023, time=2023-11-08, status=1, ipAttribution=福建省), GetPortalCommentsPageByObjectIdResponse(id=2130024, encodeId=eda7213002442, content=生信加细胞功能验证好不好投这个刊？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=35, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7ff98516862, createdName=ms2000000795035219, createdTime=Thu May 04 11:54:01 CST 2023, time=2023-05-04, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=857532, encodeId=7b3085e532d3, content=1月3投 1月8号undereview 1月20号小修五天 1月30号大修十天 2月7号修回 2月8号接收 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=95, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5bf15414154, createdName=ms3508121495608353, createdTime=Sun Feb 16 14:11:14 CST 2020, time=2020-02-16, status=1, ipAttribution=)]

2022-08-19 ms8000000344893328

审稿速度:1.0 | 投稿命中率:95.0
偏重的研究方向：神经病学;表观遗传学
经验分享：Submission Received：25 July 2022
Submission Revision Date: 15 August 2022
Accepted: 18 August 2022
本人是写的综述，方向比较窄但还算新，前期被拒了很多次，就试了这个，审稿速度非常快，审稿人的意见也非常nice！虽然中间因为找不到审稿人一度觉得稿子又要被拒了，但编辑都非常的和善！就算是自己出了一点点小问题也不用那么担心，真的是非常棒的期刊！

72 6

展开6条回复

[GetPortalCommentsPageByObjectIdResponse(id=955355, encodeId=1dba95535579, content=审稿速度:2.0 | 投稿命中率:50.0 经验分享：3.5 投稿 3.10 under review 3.24 major revised 3.29 resubmited 4.7 minor revised 4.7 resubmited 4.8 accepted 审稿很有效率，审稿人也很耐心专业，问题很尖锐，知道哪里是痛点……, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=142, replyNumber=15, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=34a12034709, createdName=1891e859aem, createdTime=Fri Apr 09 00:42:05 CST 2021, time=2021-04-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1208392, encodeId=2e5f1208392a9, content=审稿速度:2.0 | 投稿命中率:25.0 偏重的研究方向：分子相关 经验分享：投过，正文和sup的western需要原始扫描图片，投之前请准备好, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=73, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/08/29/61916d37f00260943d1aefc338a64a59.jpg, createdBy=9ee81954970, createdName=柠檬cherry, createdTime=Sun Apr 03 17:35:10 CST 2022, time=2022-04-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2111397, encodeId=c435211139ec9, content=审稿速度:3.0 | 投稿命中率:50.0 偏重的研究方向：肿瘤 经验分享：送审要多久才能有一审结果，得两周以上吗，着急毕业, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=37, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6cd78382265, createdName=ms8000000557693802, createdTime=Wed Jan 25 11:25:11 CST 2023, time=2023-01-25, status=1, ipAttribution=陕西省), GetPortalCommentsPageByObjectIdResponse(id=1227071, encodeId=488a122e0710a, content=审稿速度:2.0 偏重的研究方向：蛋白;疾病;综述 经验分享：5.10第一次提交 5.25大修 6.2修回 6.10小修 6.13修回 6.14接收, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=74, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=96625632699, createdName=ms6000001129672915, createdTime=Fri Jun 17 17:02:56 CST 2022, time=2022-06-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1239747, encodeId=5d321239e47f3, content=审稿速度:1.0 | 投稿命中率:95.0 偏重的研究方向：神经病学;表观遗传学 经验分享：Submission Received：25 July 2022 Submission Revision Date: 15 August 2022 Accepted: 18 August 2022 本人是写的综述，方向比较窄但还算新，前期被拒了很多次，就试了这个，审稿速度非常快，审稿人的意见也非常nice！虽然中间因为找不到审稿人一度觉得稿子又要被拒了，但编辑都非常的和善！就算是自己出了一点点小问题也不用那么担心，真的是非常棒的期刊！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=72, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a8078157728, createdName=ms8000000344893328, createdTime=Fri Aug 19 15:45:06 CST 2022, time=2022-08-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1249357, encodeId=8746124935ee5, content=我想请问一下哈，under review是到审稿人那边了吗，还是说可能还在编辑手里啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=39, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b9f88197404, createdName=ms5000001050298954, createdTime=Fri Sep 16 16:03:31 CST 2022, time=2022-09-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2117098, encodeId=ffee211e098fe, content=偏重的研究方向：分子机制 经验分享：2.9号投稿，一周后邮件催编辑送审或拒稿，马上让改成communication，2.22送审，目前under review中，希望快快接收, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=33, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b0258470999, createdName=ms9000000723499418, createdTime=Wed Mar 01 19:39:35 CST 2023, time=2023-03-01, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2167430, encodeId=8502216e43081, content=审稿速度:1.0 | 投稿命中率:50.0 经验分享：11月1日投，11月8号大修, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=34, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=388d9023198, createdName=ms6000000755861927, createdTime=Wed Nov 08 16:52:00 CST 2023, time=2023-11-08, status=1, ipAttribution=福建省), GetPortalCommentsPageByObjectIdResponse(id=2130024, encodeId=eda7213002442, content=生信加细胞功能验证好不好投这个刊？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=35, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7ff98516862, createdName=ms2000000795035219, createdTime=Thu May 04 11:54:01 CST 2023, time=2023-05-04, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=857532, encodeId=7b3085e532d3, content=1月3投 1月8号undereview 1月20号小修五天 1月30号大修十天 2月7号修回 2月8号接收 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=95, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5bf15414154, createdName=ms3508121495608353, createdTime=Sun Feb 16 14:11:14 CST 2020, time=2020-02-16, status=1, ipAttribution=)]

2022-09-16 ms5000001050298954

我想请问一下哈，under review是到审稿人那边了吗，还是说可能还在编辑手里啊

39 5

展开5条回复

[GetPortalCommentsPageByObjectIdResponse(id=955355, encodeId=1dba95535579, content=审稿速度:2.0 | 投稿命中率:50.0 经验分享：3.5 投稿 3.10 under review 3.24 major revised 3.29 resubmited 4.7 minor revised 4.7 resubmited 4.8 accepted 审稿很有效率，审稿人也很耐心专业，问题很尖锐，知道哪里是痛点……, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=142, replyNumber=15, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=34a12034709, createdName=1891e859aem, createdTime=Fri Apr 09 00:42:05 CST 2021, time=2021-04-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1208392, encodeId=2e5f1208392a9, content=审稿速度:2.0 | 投稿命中率:25.0 偏重的研究方向：分子相关 经验分享：投过，正文和sup的western需要原始扫描图片，投之前请准备好, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=73, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/08/29/61916d37f00260943d1aefc338a64a59.jpg, createdBy=9ee81954970, createdName=柠檬cherry, createdTime=Sun Apr 03 17:35:10 CST 2022, time=2022-04-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2111397, encodeId=c435211139ec9, content=审稿速度:3.0 | 投稿命中率:50.0 偏重的研究方向：肿瘤 经验分享：送审要多久才能有一审结果，得两周以上吗，着急毕业, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=37, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6cd78382265, createdName=ms8000000557693802, createdTime=Wed Jan 25 11:25:11 CST 2023, time=2023-01-25, status=1, ipAttribution=陕西省), GetPortalCommentsPageByObjectIdResponse(id=1227071, encodeId=488a122e0710a, content=审稿速度:2.0 偏重的研究方向：蛋白;疾病;综述 经验分享：5.10第一次提交 5.25大修 6.2修回 6.10小修 6.13修回 6.14接收, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=74, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=96625632699, createdName=ms6000001129672915, createdTime=Fri Jun 17 17:02:56 CST 2022, time=2022-06-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1239747, encodeId=5d321239e47f3, content=审稿速度:1.0 | 投稿命中率:95.0 偏重的研究方向：神经病学;表观遗传学 经验分享：Submission Received：25 July 2022 Submission Revision Date: 15 August 2022 Accepted: 18 August 2022 本人是写的综述，方向比较窄但还算新，前期被拒了很多次，就试了这个，审稿速度非常快，审稿人的意见也非常nice！虽然中间因为找不到审稿人一度觉得稿子又要被拒了，但编辑都非常的和善！就算是自己出了一点点小问题也不用那么担心，真的是非常棒的期刊！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=72, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a8078157728, createdName=ms8000000344893328, createdTime=Fri Aug 19 15:45:06 CST 2022, time=2022-08-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1249357, encodeId=8746124935ee5, content=我想请问一下哈，under review是到审稿人那边了吗，还是说可能还在编辑手里啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=39, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b9f88197404, createdName=ms5000001050298954, createdTime=Fri Sep 16 16:03:31 CST 2022, time=2022-09-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2117098, encodeId=ffee211e098fe, content=偏重的研究方向：分子机制 经验分享：2.9号投稿，一周后邮件催编辑送审或拒稿，马上让改成communication，2.22送审，目前under review中，希望快快接收, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=33, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b0258470999, createdName=ms9000000723499418, createdTime=Wed Mar 01 19:39:35 CST 2023, time=2023-03-01, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2167430, encodeId=8502216e43081, content=审稿速度:1.0 | 投稿命中率:50.0 经验分享：11月1日投，11月8号大修, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=34, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=388d9023198, createdName=ms6000000755861927, createdTime=Wed Nov 08 16:52:00 CST 2023, time=2023-11-08, status=1, ipAttribution=福建省), GetPortalCommentsPageByObjectIdResponse(id=2130024, encodeId=eda7213002442, content=生信加细胞功能验证好不好投这个刊？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=35, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7ff98516862, createdName=ms2000000795035219, createdTime=Thu May 04 11:54:01 CST 2023, time=2023-05-04, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=857532, encodeId=7b3085e532d3, content=1月3投 1月8号undereview 1月20号小修五天 1月30号大修十天 2月7号修回 2月8号接收 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=95, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5bf15414154, createdName=ms3508121495608353, createdTime=Sun Feb 16 14:11:14 CST 2020, time=2020-02-16, status=1, ipAttribution=)]

2023-03-01 ms9000000723499418 来自山东省

偏重的研究方向：分子机制
经验分享：2.9号投稿，一周后邮件催编辑送审或拒稿，马上让改成communication，2.22送审，目前under review中，希望快快接收

33 5

展开5条回复

[GetPortalCommentsPageByObjectIdResponse(id=955355, encodeId=1dba95535579, content=审稿速度:2.0 | 投稿命中率:50.0 经验分享：3.5 投稿 3.10 under review 3.24 major revised 3.29 resubmited 4.7 minor revised 4.7 resubmited 4.8 accepted 审稿很有效率，审稿人也很耐心专业，问题很尖锐，知道哪里是痛点……, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=142, replyNumber=15, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=34a12034709, createdName=1891e859aem, createdTime=Fri Apr 09 00:42:05 CST 2021, time=2021-04-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1208392, encodeId=2e5f1208392a9, content=审稿速度:2.0 | 投稿命中率:25.0 偏重的研究方向：分子相关 经验分享：投过，正文和sup的western需要原始扫描图片，投之前请准备好, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=73, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/08/29/61916d37f00260943d1aefc338a64a59.jpg, createdBy=9ee81954970, createdName=柠檬cherry, createdTime=Sun Apr 03 17:35:10 CST 2022, time=2022-04-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2111397, encodeId=c435211139ec9, content=审稿速度:3.0 | 投稿命中率:50.0 偏重的研究方向：肿瘤 经验分享：送审要多久才能有一审结果，得两周以上吗，着急毕业, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=37, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6cd78382265, createdName=ms8000000557693802, createdTime=Wed Jan 25 11:25:11 CST 2023, time=2023-01-25, status=1, ipAttribution=陕西省), GetPortalCommentsPageByObjectIdResponse(id=1227071, encodeId=488a122e0710a, content=审稿速度:2.0 偏重的研究方向：蛋白;疾病;综述 经验分享：5.10第一次提交 5.25大修 6.2修回 6.10小修 6.13修回 6.14接收, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=74, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=96625632699, createdName=ms6000001129672915, createdTime=Fri Jun 17 17:02:56 CST 2022, time=2022-06-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1239747, encodeId=5d321239e47f3, content=审稿速度:1.0 | 投稿命中率:95.0 偏重的研究方向：神经病学;表观遗传学 经验分享：Submission Received：25 July 2022 Submission Revision Date: 15 August 2022 Accepted: 18 August 2022 本人是写的综述，方向比较窄但还算新，前期被拒了很多次，就试了这个，审稿速度非常快，审稿人的意见也非常nice！虽然中间因为找不到审稿人一度觉得稿子又要被拒了，但编辑都非常的和善！就算是自己出了一点点小问题也不用那么担心，真的是非常棒的期刊！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=72, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a8078157728, createdName=ms8000000344893328, createdTime=Fri Aug 19 15:45:06 CST 2022, time=2022-08-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1249357, encodeId=8746124935ee5, content=我想请问一下哈，under review是到审稿人那边了吗，还是说可能还在编辑手里啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=39, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b9f88197404, createdName=ms5000001050298954, createdTime=Fri Sep 16 16:03:31 CST 2022, time=2022-09-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2117098, encodeId=ffee211e098fe, content=偏重的研究方向：分子机制 经验分享：2.9号投稿，一周后邮件催编辑送审或拒稿，马上让改成communication，2.22送审，目前under review中，希望快快接收, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=33, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b0258470999, createdName=ms9000000723499418, createdTime=Wed Mar 01 19:39:35 CST 2023, time=2023-03-01, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2167430, encodeId=8502216e43081, content=审稿速度:1.0 | 投稿命中率:50.0 经验分享：11月1日投，11月8号大修, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=34, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=388d9023198, createdName=ms6000000755861927, createdTime=Wed Nov 08 16:52:00 CST 2023, time=2023-11-08, status=1, ipAttribution=福建省), GetPortalCommentsPageByObjectIdResponse(id=2130024, encodeId=eda7213002442, content=生信加细胞功能验证好不好投这个刊？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=35, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7ff98516862, createdName=ms2000000795035219, createdTime=Thu May 04 11:54:01 CST 2023, time=2023-05-04, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=857532, encodeId=7b3085e532d3, content=1月3投 1月8号undereview 1月20号小修五天 1月30号大修十天 2月7号修回 2月8号接收 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=95, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5bf15414154, createdName=ms3508121495608353, createdTime=Sun Feb 16 14:11:14 CST 2020, time=2020-02-16, status=1, ipAttribution=)]

2023-11-08 ms6000000755861927 来自福建省

审稿速度:1.0 | 投稿命中率:50.0
经验分享：11月1日投，11月8号大修

34 4

展开4条回复

[GetPortalCommentsPageByObjectIdResponse(id=955355, encodeId=1dba95535579, content=审稿速度:2.0 | 投稿命中率:50.0 经验分享：3.5 投稿 3.10 under review 3.24 major revised 3.29 resubmited 4.7 minor revised 4.7 resubmited 4.8 accepted 审稿很有效率，审稿人也很耐心专业，问题很尖锐，知道哪里是痛点……, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=142, replyNumber=15, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=34a12034709, createdName=1891e859aem, createdTime=Fri Apr 09 00:42:05 CST 2021, time=2021-04-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1208392, encodeId=2e5f1208392a9, content=审稿速度:2.0 | 投稿命中率:25.0 偏重的研究方向：分子相关 经验分享：投过，正文和sup的western需要原始扫描图片，投之前请准备好, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=73, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/08/29/61916d37f00260943d1aefc338a64a59.jpg, createdBy=9ee81954970, createdName=柠檬cherry, createdTime=Sun Apr 03 17:35:10 CST 2022, time=2022-04-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2111397, encodeId=c435211139ec9, content=审稿速度:3.0 | 投稿命中率:50.0 偏重的研究方向：肿瘤 经验分享：送审要多久才能有一审结果，得两周以上吗，着急毕业, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=37, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6cd78382265, createdName=ms8000000557693802, createdTime=Wed Jan 25 11:25:11 CST 2023, time=2023-01-25, status=1, ipAttribution=陕西省), GetPortalCommentsPageByObjectIdResponse(id=1227071, encodeId=488a122e0710a, content=审稿速度:2.0 偏重的研究方向：蛋白;疾病;综述 经验分享：5.10第一次提交 5.25大修 6.2修回 6.10小修 6.13修回 6.14接收, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=74, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=96625632699, createdName=ms6000001129672915, createdTime=Fri Jun 17 17:02:56 CST 2022, time=2022-06-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1239747, encodeId=5d321239e47f3, content=审稿速度:1.0 | 投稿命中率:95.0 偏重的研究方向：神经病学;表观遗传学 经验分享：Submission Received：25 July 2022 Submission Revision Date: 15 August 2022 Accepted: 18 August 2022 本人是写的综述，方向比较窄但还算新，前期被拒了很多次，就试了这个，审稿速度非常快，审稿人的意见也非常nice！虽然中间因为找不到审稿人一度觉得稿子又要被拒了，但编辑都非常的和善！就算是自己出了一点点小问题也不用那么担心，真的是非常棒的期刊！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=72, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a8078157728, createdName=ms8000000344893328, createdTime=Fri Aug 19 15:45:06 CST 2022, time=2022-08-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1249357, encodeId=8746124935ee5, content=我想请问一下哈，under review是到审稿人那边了吗，还是说可能还在编辑手里啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=39, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b9f88197404, createdName=ms5000001050298954, createdTime=Fri Sep 16 16:03:31 CST 2022, time=2022-09-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2117098, encodeId=ffee211e098fe, content=偏重的研究方向：分子机制 经验分享：2.9号投稿，一周后邮件催编辑送审或拒稿，马上让改成communication，2.22送审，目前under review中，希望快快接收, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=33, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b0258470999, createdName=ms9000000723499418, createdTime=Wed Mar 01 19:39:35 CST 2023, time=2023-03-01, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2167430, encodeId=8502216e43081, content=审稿速度:1.0 | 投稿命中率:50.0 经验分享：11月1日投，11月8号大修, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=34, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=388d9023198, createdName=ms6000000755861927, createdTime=Wed Nov 08 16:52:00 CST 2023, time=2023-11-08, status=1, ipAttribution=福建省), GetPortalCommentsPageByObjectIdResponse(id=2130024, encodeId=eda7213002442, content=生信加细胞功能验证好不好投这个刊？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=35, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7ff98516862, createdName=ms2000000795035219, createdTime=Thu May 04 11:54:01 CST 2023, time=2023-05-04, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=857532, encodeId=7b3085e532d3, content=1月3投 1月8号undereview 1月20号小修五天 1月30号大修十天 2月7号修回 2月8号接收 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=95, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5bf15414154, createdName=ms3508121495608353, createdTime=Sun Feb 16 14:11:14 CST 2020, time=2020-02-16, status=1, ipAttribution=)]

2023-05-04 ms2000000795035219 来自广东省

生信加细胞功能验证好不好投这个刊？

35 4

展开4条回复

[GetPortalCommentsPageByObjectIdResponse(id=955355, encodeId=1dba95535579, content=审稿速度:2.0 | 投稿命中率:50.0 经验分享：3.5 投稿 3.10 under review 3.24 major revised 3.29 resubmited 4.7 minor revised 4.7 resubmited 4.8 accepted 审稿很有效率，审稿人也很耐心专业，问题很尖锐，知道哪里是痛点……, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=142, replyNumber=15, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=34a12034709, createdName=1891e859aem, createdTime=Fri Apr 09 00:42:05 CST 2021, time=2021-04-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1208392, encodeId=2e5f1208392a9, content=审稿速度:2.0 | 投稿命中率:25.0 偏重的研究方向：分子相关 经验分享：投过，正文和sup的western需要原始扫描图片，投之前请准备好, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=73, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/08/29/61916d37f00260943d1aefc338a64a59.jpg, createdBy=9ee81954970, createdName=柠檬cherry, createdTime=Sun Apr 03 17:35:10 CST 2022, time=2022-04-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2111397, encodeId=c435211139ec9, content=审稿速度:3.0 | 投稿命中率:50.0 偏重的研究方向：肿瘤 经验分享：送审要多久才能有一审结果，得两周以上吗，着急毕业, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=37, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6cd78382265, createdName=ms8000000557693802, createdTime=Wed Jan 25 11:25:11 CST 2023, time=2023-01-25, status=1, ipAttribution=陕西省), GetPortalCommentsPageByObjectIdResponse(id=1227071, encodeId=488a122e0710a, content=审稿速度:2.0 偏重的研究方向：蛋白;疾病;综述 经验分享：5.10第一次提交 5.25大修 6.2修回 6.10小修 6.13修回 6.14接收, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=74, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=96625632699, createdName=ms6000001129672915, createdTime=Fri Jun 17 17:02:56 CST 2022, time=2022-06-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1239747, encodeId=5d321239e47f3, content=审稿速度:1.0 | 投稿命中率:95.0 偏重的研究方向：神经病学;表观遗传学 经验分享：Submission Received：25 July 2022 Submission Revision Date: 15 August 2022 Accepted: 18 August 2022 本人是写的综述，方向比较窄但还算新，前期被拒了很多次，就试了这个，审稿速度非常快，审稿人的意见也非常nice！虽然中间因为找不到审稿人一度觉得稿子又要被拒了，但编辑都非常的和善！就算是自己出了一点点小问题也不用那么担心，真的是非常棒的期刊！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=72, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a8078157728, createdName=ms8000000344893328, createdTime=Fri Aug 19 15:45:06 CST 2022, time=2022-08-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1249357, encodeId=8746124935ee5, content=我想请问一下哈，under review是到审稿人那边了吗，还是说可能还在编辑手里啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=39, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b9f88197404, createdName=ms5000001050298954, createdTime=Fri Sep 16 16:03:31 CST 2022, time=2022-09-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2117098, encodeId=ffee211e098fe, content=偏重的研究方向：分子机制 经验分享：2.9号投稿，一周后邮件催编辑送审或拒稿，马上让改成communication，2.22送审，目前under review中，希望快快接收, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=33, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b0258470999, createdName=ms9000000723499418, createdTime=Wed Mar 01 19:39:35 CST 2023, time=2023-03-01, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2167430, encodeId=8502216e43081, content=审稿速度:1.0 | 投稿命中率:50.0 经验分享：11月1日投，11月8号大修, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=34, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=388d9023198, createdName=ms6000000755861927, createdTime=Wed Nov 08 16:52:00 CST 2023, time=2023-11-08, status=1, ipAttribution=福建省), GetPortalCommentsPageByObjectIdResponse(id=2130024, encodeId=eda7213002442, content=生信加细胞功能验证好不好投这个刊？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=35, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7ff98516862, createdName=ms2000000795035219, createdTime=Thu May 04 11:54:01 CST 2023, time=2023-05-04, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=857532, encodeId=7b3085e532d3, content=1月3投 1月8号undereview 1月20号小修五天 1月30号大修十天 2月7号修回 2月8号接收 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=95, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5bf15414154, createdName=ms3508121495608353, createdTime=Sun Feb 16 14:11:14 CST 2020, time=2020-02-16, status=1, ipAttribution=)]

2020-02-16 ms3508121495608353

1月3投
1月8号undereview
1月20号小修五天
1月30号大修十天
2月7号修回
2月8号接收

95 4

展开4条回复

内科

外科

专科科室

热点

按科室浏览

临床工具

科研工具

其他工具

科研数智化

真实世界研究解决方案

数字化学术传播解决方案

其它

期刊讨论

科室

工具

服务